Core Viewpoint - Clearmind Medicine Inc. is implementing a 1-for-40 reverse stock split to comply with Nasdaq's minimum bid price requirement, following a significant decline in its stock price and market capitalization [2][4]. Group 1: Stock Performance - Clearmind Medicine shares fell 29.92% in after-hours trading, closing at $0.0801, down 6.08% on the day [1]. - The stock has experienced a 91.41% decline over the past year, with a market capitalization of $6.86 million [5]. Group 2: Reverse Stock Split Details - The reverse stock split will reduce the outstanding common shares from 59.99 million to 1.50 million, effective December 15 [3]. - The company's authorized share capital will remain unchanged, and no fractional shares will be issued, with all fractions rounded up to the nearest whole share [3]. Group 3: Board Approval and Adjustments - The board of directors approved the reverse split on November 12, in accordance with the company's articles of association [4]. - A proportionate adjustment will be made to the per-share exercise price and the number of shares issuable upon exercise of all outstanding options and warrants [4].

Core Viewpoint - Clearmind Medicine Inc. will conduct a reverse share split at a ratio of 1-for-40 to regain compliance with the Nasdaq Minimum Bid Price Rule, effective December 15, 2025 [1][2]. Group 1: Reverse Share Split Details - The reverse share split was approved by the Company's board of directors on November 12, 2025 [2]. - Following the reverse split, the number of issued and outstanding Common Shares will decrease from 59,991,852 to 1,499,796 [3]. - No fractional Common Shares will be issued; all fractional shares will be rounded up to the nearest whole share [4]. Group 2: Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics for under-treated health issues, including alcohol use disorder [5]. - The Company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [5].

Core Viewpoint - Clearmind Medicine Inc. has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, as its closing bid price has been below $1.00 for the last 30 consecutive business days [1][2]. Compliance Period - The company has been granted a 180-calendar day compliance period until June 2, 2026, to regain compliance with the minimum bid price requirement [2]. - During this compliance period, the company's shares will continue to be listed and traded on Nasdaq under the symbol "CMND" [2]. Regaining Compliance - To regain compliance, the closing bid price must meet or exceed $1.00 per share for at least 10 consecutive business days during the compliance period [2]. - If compliance is not achieved by June 2, 2026, the company may qualify for a second 180-calendar day compliance period, provided it meets other listing requirements [3]. Monitoring and Future Actions - The company intends to monitor its closing bid price and will consider options to resolve the non-compliance issue as necessary [4]. - There is no assurance that the company will regain compliance with the minimum bid price requirement or other Nasdaq listing criteria [4]. Company Overview - Clearmind Medicine Inc. is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address under-treated health issues, including alcohol use disorder [5]. - The company holds a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [5].

As filed with the Securities and Exchange Commission on December 5, 2025. Registration No. 333-291817 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. (Exact name of registrant as specified in its charter) | British Columbia | 2834 | Not Applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organiz ...

Core Insights - Clearmind Medicine Inc. has enrolled and dosed the first participant in its Phase I/IIa clinical trial for Alcohol Use Disorder (AUD) with its proprietary drug candidate CMND-100 at Hadassah-University Medical Center in Jerusalem, marking a significant milestone in the trial [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address major under-treated health issues, including AUD [1][4] - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4] Clinical Trial Details - The trial at Hadassah-University Medical Center is led by Prof. Joseph Caraco and evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in AUD patients [2] - Recent positive results from the first cohort and a unanimous recommendation from the Data and Safety Monitoring Board support the continuation of the trial [2] Intellectual Property - Clearmind's intellectual portfolio includes nineteen patent families with 31 granted patents, and the company plans to seek additional patents as warranted [5]

Core Insights - Clearmind Medicine Inc. has announced significant progress in its FDA-approved Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic oral therapy targeting Alcohol Use Disorder (AUD) [1][2][3] Group 1: Clinical Trial Progress - The company reported positive top-line results from the first cohort of six participants, dosed at prestigious institutions including Johns Hopkins University and Yale University [4] - The independent Data and Safety Monitoring Board (DSMB) unanimously approved the continuation of the clinical trial after an interim safety review [5] - Enrollment has commenced at a new clinical site in Israel, Tel Aviv Sourasky Medical Center, enhancing patient recruitment efforts [6] Group 2: Market Context and Impact - AUD affects over 28 million adults in the U.S., incurring societal and economic costs exceeding $249 billion annually, highlighting the need for effective treatments [3] - Current treatment options for AUD are limited in efficacy and accessibility, positioning Clearmind's CMND-100 as a potentially transformative solution [3] Group 3: Company Overview - Clearmind is focused on developing novel neuroplastogen-derived therapeutics to address significant health issues, including AUD [7] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans for further acquisitions [8]

As filed with the Securities and Exchange Commission on November 26, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. (Exact name of registrant as specified in its charter) British Columbia 2834 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 101 ...

Core Insights - Clearmind Medicine Inc. (NASDAQ:CMND) experienced a 7.09% increase in pre-market trading, reaching a price of $0.1713 after closing at $0.16, which was a decline of 19.4% on the previous day [1][6]. Group 1: Clinical Trial Developments - The company announced that Tel Aviv Sourasky Medical Center (TASMC) has enrolled the first participant in its multinational Phase I/IIa clinical trial of CMND-100 for alcohol use disorder, which has received approval from the U.S. Food and Drug Administration [2]. - TASMC is part of an expanded trial network that includes Yale School of Medicine, Johns Hopkins University School of Medicine, and Hadassah Medical Center for patient screening and enrollment [3]. - The Phase I/IIa trial is designed to assess the pharmacokinetics, safety, tolerability, and initial efficacy of CMND-100, an oral MEAI-based medication that is not hallucinogenic, with the first cohort's top-line results indicating no significant adverse events [5]. Group 2: Executive Commentary and Stock Performance - Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, stated that the recruitment of the first patient at TASMC is a significant step that accelerates the global trial [6]. - The company's stock has seen a substantial decline of 88.97% year-to-date, with a 52-week price range of $0.15 to $2.18 and a market capitalization of $5.26 million [6].

Core Insights - Clearmind Medicine Inc. has commenced patient enrollment for its Phase I/IIa clinical trial of CMND-100 for Alcohol Use Disorder (AUD) at Tel Aviv Sourasky Medical Center, marking a significant milestone in the global study [1][2][4] - The trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100, a non-hallucinogenic, oral MEAI-based compound, with initial results indicating excellent safety and adherence [3][4] - Clearmind's intellectual property portfolio includes nineteen patent families with 31 granted patents, and the company plans to pursue additional patents to enhance its portfolio [5] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address under-treated health issues, particularly AUD [1][4] - The company is committed to researching and commercializing psychedelic-based compounds as regulated medicines, foods, or supplements [4] Clinical Trial Details - The Phase I/IIa trial is being conducted at multiple prestigious sites, including Yale School of Medicine and Johns Hopkins University, in addition to TASMC [2] - The first completed cohort of the trial has shown no serious adverse events, indicating a positive safety profile for CMND-100 [3]

Core Insights - Clearmind Medicine Inc. has received a positive recommendation from its independent Data and Safety Monitoring Board (DSMB) to continue its Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic neuroplastogen aimed at treating Alcohol Use Disorder (AUD) [1][2][3] Group 1: Clinical Trial Details - The ongoing multinational, multi-center trial is assessing the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of CMND-100 in reducing alcohol cravings and consumption among individuals with moderate to severe AUD [2] - The DSMB's review highlighted a favorable safety profile with no serious adverse events reported and general good tolerability across all participants [6] Group 2: Company Statements and Future Outlook - The CEO of Clearmind expressed confidence in CMND-100's safety and therapeutic potential, indicating that the positive interim data positions the company to accelerate enrollment in the trial [3] - The DSMB was established in 2023 to ensure patient safety and data integrity throughout the trial, reflecting the company's commitment to ethical clinical development [3] Group 3: Company Background and Intellectual Property - Clearmind is focused on developing novel psychedelic-derived therapeutics to address significant health issues, including AUD, with the goal of commercializing these compounds as regulated medicines [4] - The company holds an intellectual property portfolio consisting of nineteen patent families, including 31 granted patents, and plans to seek additional patents as warranted [5]